肝硬化并发自发性细菌性腹膜炎的研究进展
Advances in Liver Cirrhosis Complicated with Spontaneous Bacterial Peritonitis
DOI: 10.12677/acm.2025.15113146, PDF,    科研立项经费支持
作者: 蔡 昕, 郑积才, 曾如雪*：江山市人民医院感染科，浙江 江山；赵冬冬：江山市人民医院感染科，浙江 江山；浙江大学医学院附属邵逸夫医院感染科，浙江 杭州
关键词: 肝硬化；自发性细菌性腹膜炎；诊断；防治；新型生物标志物；Liver Cirrhosis； Spontaneous Bacterial Peritonitis； Diagnosis； Prevention and Treatment； Novel Biomarkers
摘要: 自发性细菌性腹膜炎(Spontaneous Bacterial Peritonitis, SBP)是肝硬化腹水患者常见且严重的并发症，因其临床表现不典型、起病隐匿，诊断常面临挑战。部分患者病情进展迅猛，病死率高，故早期识别与干预对改善预后至关重要。本文围绕肝硬化并发SBP的发病机制、诊断策略、治疗进展及预防措施进行综述，重点探讨肠道菌群失调、免疫微环境改变在SBP发生中的作用，以及新型生物标志物、微生态调节等前沿方向，以期为临床防治提供新视角和参考依据。
Abstract: Spontaneous Bacterial Peritonitis (SBP) is a common and serious complication in patients with ascites due to liver cirrhosis. Due to its atypical clinical manifestations and insidious onset, diagnosis often faces challenges. Some patients experience rapid disease progression and a high mortality rate. Therefore, early identification and intervention are crucial for improving prognosis. This review summarizes current understanding of the pathogenesis, diagnostic strategies, treatment progress and preventive measures of liver cirrhosis complicated with SBP. We particularly focus on discussing the role of intestinal flora imbalance and changes in the immune microenvironment in the occurrence of SBP, as well as emerging areas including novel biomarkers and microecological modulation, with the aim of providing new perspectives and a reference basis for clinical prevention and treatment.
文章引用：蔡昕, 郑积才, 赵冬冬, 曾如雪. 肝硬化并发自发性细菌性腹膜炎的研究进展[J]. 临床医学进展, 2025, 15(11): 679-685. https://doi.org/10.12677/acm.2025.15113146

参考文献

[1] Reiberger, T., Püspök, A., Schoder, M., Baumann-Durchschein, F., Bucsics, T., Datz, C., et al. (2017) Austrian Consensus Guidelines on the Management and Treatment of Portal Hypertension (Billroth III). Wiener klinische Wochenschrift, 129, 135-158. [Google Scholar] [CrossRef] [PubMed]
[2] Aithal, G.P., Palaniyappan, N., China, L., Härmälä, S., Macken, L., Ryan, J.M., et al. (2020) Guidelines on the Management of Ascites in Cirrhosis. Gut, 70, 9-29. [Google Scholar] [CrossRef] [PubMed]
[3] 中华医学会肝病学分会. 肝硬化腹水诊疗指南(2023年版) [J]. 中华肝脏病杂志, 2023, 31(8): 813-826.
[4] Maccauro, V., Airola, C., Santopaolo, F., Gasbarrini, A., Ponziani, F.R. and Pompili, M. (2023) Gut Microbiota and Infectious Complications in Advanced Chronic Liver Disease: Focus on Spontaneous Bacterial Peritonitis. Life, 13, Article 991. [Google Scholar] [CrossRef] [PubMed]
[5] Tuchendler, E., Tuchendler, P.K. and Madej, G. (2018) Immunodeficiency Caused by Cirrhosis. Clinical and Experimental Hepatology, 4, 158-164. [Google Scholar] [CrossRef] [PubMed]
[6] Yang, L., Liu, S., Qiu, C., Zhang, Q., Zhang, C. and Jin, Z. (2025) Elevated Ascitic Interleukin-36 Receptor Antagonist Mediates CD8+ T Cell Exhaustion in Vitro in Liver Cirrhotic Patients with Spontaneous Bacterial Peritonitis. Immunology Letters, 276, Article ID: 107061. [Google Scholar] [CrossRef] [PubMed]
[7] Murad, M., Reuken, P.A., Schubert, K., Reißing, J., Ibidapo-Obe, O., Große, K., et al. (2025) The Prognostic Significance of Hdl-Associated Apolipoproteins in Ascitic Fluid from Patients with Cirrhosis and Spontaneous Bacterial Peritonitis. Scientific Reports, 15, Article No. 25714. [Google Scholar] [CrossRef] [PubMed]
[8] Tapper, E.B. and Parikh, N.D. (2023) Diagnosis and Management of Cirrhosis and Its Complications. JAMA, 329, 1589-1602. [Google Scholar] [CrossRef] [PubMed]
[9] Biggins, S.W., Angeli, P., Garcia‐Tsao, G., Ginès, P., Ling, S.C., Nadim, M.K., et al. (2021) Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 74, 1014-1048. [Google Scholar] [CrossRef] [PubMed]
[10] 李条焕, 李晓, 王洋. 自发性细菌性腹膜炎患者腹水中病原菌分布特点及药敏结果分析[J]. 现代诊断与治疗, 2021, 32(11): 1771-1772.
[11] 段瑞娴, 血清降钙素原联合C反应蛋白及白细胞介素-6对肝硬化腹水自发性腹膜炎的诊断价值[J]. 中国实用医刊, 2019, 46(3): 58-60.
[12] Patel, K.P., Korbitz, P.M., Gallagher, J.P., Schmidt, C., Ingviya, T. and Manatsathit, W. (2022) Ascitic Calprotectin and Lactoferrin for Detection of Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-Analysis. Translational Gastroenterology and Hepatology, 7, Article 37. [Google Scholar] [CrossRef] [PubMed]
[13] 郑俊福, 李磊. 放宽肝硬化腹水中性多核粒细胞的诊断标准对自发性细菌性腹膜炎的早期诊断价值[J]. 胃肠病学和肝病学杂志, 2019, 28(7): 740-743.
[14] BSG: British Society of Gastroenterology (2021) Guidelines on the Management of Ascites in Cirrhosis. Gut, 70, 9-29.
[15] 李雅欣, 丁惠国. 人血白蛋白在肝硬化及其并发症中的应用[J]. 临床肝胆病杂志, 2025, 41(3): 409-414.
[16] Ebied, A.M., Rattanasuwan, T., Chen, Y. and Khoury, A.P. (2021) Albumin Utilization in Spontaneous Bacterial Peritonitis. Journal of Pharmacy Practice, 35, 546-550. [Google Scholar] [CrossRef] [PubMed]
[17] 谢颖, 赵勇娜. 肝硬化腹水患者肠道菌群变化对自发性腹膜炎的预测效能分析[J]. 淮海医药, 2023, 41(6): 580-584.
[18] Lechner, S., Yee, M., Limketkai, B.N. and Pham, E.A. (2020) Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction. Digestive Diseases and Sciences, 65, 897-905. [Google Scholar] [CrossRef] [PubMed]
[19] 买热木古·阿布都热依木, 方法, 穆清爽, 等. 调节肠道菌群微生态对老年肝硬化患者腹膜炎治疗效果和预后的影响[J]. 实用医学杂杂, 2021, 37(3): 343-347.
[20] Yokoyama, K., Fukuda, H., Yamauchi, R., Higashi, M., Miyayama, T., Higashi, T., et al. (2022) Long-Term Effects of Rifaximin on Patients with Hepatic Encephalopathy: Its Possible Effects on the Improvement in the Blood Ammonia Concentration Levels, Hepatic Spare Ability and Refractory Ascites. Medicina, 58, Article 1276. [Google Scholar] [CrossRef] [PubMed]
[21] Praharaj, D.L., Premkumar, M., Roy, A., Verma, N., Taneja, S., Duseja, A., et al. (2022) Rifaximin vs. Norfloxacin for Spontaneous Bacterial Peritonitis Prophylaxis: A Randomized Controlled Trial. Journal of Clinical and Experimental Hepatology, 12, 336-342. [Google Scholar] [CrossRef] [PubMed]
[22] Markley, J.D. and Bajaj, J.S. (2025) Rethinking Antibiotic Prophylaxis for Spontaneous Bacterial Peritonitis in Patients with Cirrhosis: First, Do No Harm. Clinical Infectious Diseases, 80, 710-714. [Google Scholar] [CrossRef] [PubMed]
[23] Xu, H.B., Wang, H.D., Li, C.H., Ye, S., Dong, M.S., Xia, Q.J., et al. (2015) Proton Pump Inhibitor Use and Risk of Spontaneous Bacterial Peritonitis in Cirrhotic Patients: A Systematic Review and Meta-Analysis. Genetics and Molecular Research, 14, 7490-7501. [Google Scholar] [CrossRef] [PubMed]
[24] European Association for the Study of the Liver (2018) EASL Clinical Practice Guidelines for the Management of Patients with Decompensated Cirrhosis. Journal of Hepatology, 69, 406-460.

为你推荐